{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:25:22Z","timestamp":1751430322966,"version":"3.41.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Emergency Medicine Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.emc.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:46:25Z","timestamp":1751409985000},"page":"503-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complications of Chimeric Antigen Receptor T-cell Therapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Gregory","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.emc.2025.04.004_bib1","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.emc.2025.04.004_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.emc.2025.04.004_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib4","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia","year":"2019","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.emc.2025.04.004_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/jir.2021.0057","article-title":"Prognostic significance of cytokine release syndrome in B cell hematological malignancies patients after chimeric antigen receptor T cell therapy","volume":"41","author":"Dong","year":"2021","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"10.1016\/j.emc.2025.04.004_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.emc.2025.04.004_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","article-title":"The gasdermins, a protein family executing cell death and inflammation","volume":"20","author":"Broz","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"issue":"23","key":"10.1016\/j.emc.2025.04.004_bib12","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.emc.2025.04.004_bib13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.emc.2025.04.004_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Therapeut Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.emc.2025.04.004_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"issue":"29","key":"10.1016\/j.emc.2025.04.004_bib17","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2023.38.e232","article-title":"A comparison of the effects of dexamethasone and methylprednisolone, used on level-3 intensive care COVID-19 patients, on mortality: a multi-center retrospective study","volume":"38","author":"Sari","year":"2023","journal-title":"J Kor Med Sci"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.emc.2025.04.004_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.emc.2025.04.004_bib20","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"issue":"7735","key":"10.1016\/j.emc.2025.04.004_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.emc.2025.04.004_bib22","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.emc.2025.04.004_bib25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.emc.2025.04.004_bib26","series-title":"The EBMT\/EHA CAR-T cell handbook","first-page":"141","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022"},{"key":"10.1016\/j.emc.2025.04.004_bib27","unstructured":"IEC therapy toxicity assessment and management (also known as CARTOX) - adult. In: Center TUoTMAC, ed. 12:59 ed. Houston, Texas; 2023."},{"issue":"5","key":"10.1016\/j.emc.2025.04.004_bib28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.emc.2025.04.004_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.emc.2025.04.004_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.emc.2025.04.004_bib32","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.emc.2025.04.004_bib33","article-title":"Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000927","article-title":"Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus","volume":"8","author":"Han","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.emc.2025.04.004_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.emc.2025.04.004_bib37","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.emc.2025.04.004_bib38","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.172.4.2011","article-title":"Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification","volume":"172","author":"Danese","year":"2004","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.emc.2025.04.004_bib39","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1538-7836.2008.02989.x","article-title":"Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells","volume":"6","author":"Cao","year":"2008","journal-title":"J Thromb Haemostasis"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12185-020-02992-w","article-title":"Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies","volume":"113","author":"Ikezoe","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.emc.2025.04.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.emc.2025.04.004_bib42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"},{"issue":"16","key":"10.1016\/j.emc.2025.04.004_bib44","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.emc.2025.04.004_bib45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"70","key":"10.1016\/j.emc.2025.04.004_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.emc.2025.04.004_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.emc.2025.04.004_bib48","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.emc.2025.04.004_bib49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.emc.2025.04.004_bib50","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.emc.2025.04.004_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.18454","article-title":"Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel","volume":"199","author":"Porter","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.emc.2025.04.004_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFNgamma inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.emc.2025.04.004_bib53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.emc.2025.04.004_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.emc.2025.04.004_bib55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.emc.2025.04.004_bib56","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.emc.2025.04.004_bib57","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.emc.2025.04.004_bib58","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2567.2009.03072.x","article-title":"Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo","volume":"128","author":"Meiraz","year":"2009","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.emc.2025.04.004_bib61","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/2326-6066.CIR-18-0065","article-title":"CD30-Redirected chimeric antigen receptor T cells target CD30(+) and CD30(-) embryonal carcinoma via antigen-dependent and fas\/FasL interactions","volume":"6","author":"Hong","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"6220","key":"10.1016\/j.emc.2025.04.004_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"32","key":"10.1016\/j.emc.2025.04.004_bib63","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.emc.2025.04.004_bib65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Lymphoma program investigators at the university of P. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.emc.2025.04.004_bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.emc.2025.04.004_bib67","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.emc.2025.04.004_bib68","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.emc.2025.04.004_bib69","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.emc.2025.04.004_bib70","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.emc.2025.04.004_bib71","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired immune health in survivors of diffuse large B-cell lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Emergency Medicine Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862725000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862725000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:47:06Z","timestamp":1751410026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733862725000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0733862725000240"],"URL":"https:\/\/doi.org\/10.1016\/j.emc.2025.04.004","relation":{},"ISSN":["0733-8627"],"issn-type":[{"value":"0733-8627","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of Chimeric Antigen Receptor T-cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Emergency Medicine Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.emc.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}